Abstract
Background How could we anticipate the progression of the ongoing epidemic of the coronavirus disease 2019 (COVID-19) in China? As a measure of transmissibility, we aimed to estimate concurrently the time-varying reproduction number over time during the COVID-19 epidemic in China.
Methods We extracted the epidemic data from the “Tracking the Epidemic” website of the Chinese Center for Disease Control and Prevention for the duration of January 19, 2020 and March 14, 2020. Then, we specified two plausible distributions of serial interval to apply the novel estimation method implemented in the incidence and EpiEstim packages to the data of daily new confirmed cases for robustly estimating the time-varying reproduction number in the R software.
Results The epidemic curve of daily new confirmed cases in China peaked around February 4–6, 2020, and then declined gradually, except the very high peak on February 12, 2020 owing to the added clinically diagnosed cases of the Hubei Province. Under two specified plausible scenarios for the distribution of serial interval, both curves of the estimated time-varying reproduction numbers fell below 1.0 around February 17–18, 2020. Finally, the COVID-19 epidemic in China abated around March 7–8, 2020, indicating that the prompt and aggressive control measures of China were effective.
Conclusion Seeing the estimated time-varying reproduction number going downhill speedily was more informative than looking for the drops in the daily number of new confirmed cases during an ongoing epidemic of infectious disease. We urged public health authorities and scientists to estimate time-varying reproduction numbers routinely during an epidemic of infectious diseases and to report them daily to the public until the end of the epidemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors did not receive any funding for this study. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The epidemic data were listed in Supplementary Appendix 1.
